Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:CNTA NASDAQ:SRRK NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$5.56+3.0%$6.14$3.49▼$8.40$1.33B0.583.04 million shs4.58 million shsCNTACentessa Pharmaceuticals$39.62-0.5%$38.98$11.55▼$40.26$5.94B1.111.08 million shs1.70 million shsSRRKScholar Rock$44.30-2.3%$48.00$27.07▼$52.19$5.43B0.691.20 million shs1.15 million shsTGTXTG Therapeutics$40.16-1.0%$37.05$25.28▼$44.65$6.21B1.681.76 million shs1.79 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-0.37%-13.60%-24.26%-12.76%+46.34%CNTACentessa Pharmaceuticals-0.13%-0.03%+0.33%+53.37%+217.64%SRRKScholar Rock+1.55%-9.01%-3.82%+0.09%+47.08%TGTXTG Therapeutics+1.12%+4.48%+12.35%+38.57%+9.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$5.56+3.0%$6.14$3.49▼$8.40$1.33B0.583.04 million shs4.58 million shsCNTACentessa Pharmaceuticals$39.62-0.5%$38.98$11.55▼$40.26$5.94B1.111.08 million shs1.70 million shsSRRKScholar Rock$44.30-2.3%$48.00$27.07▼$52.19$5.43B0.691.20 million shs1.15 million shsTGTXTG Therapeutics$40.16-1.0%$37.05$25.28▼$44.65$6.21B1.681.76 million shs1.79 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-0.37%-13.60%-24.26%-12.76%+46.34%CNTACentessa Pharmaceuticals-0.13%-0.03%+0.33%+53.37%+217.64%SRRKScholar Rock+1.55%-9.01%-3.82%+0.09%+47.08%TGTXTG Therapeutics+1.12%+4.48%+12.35%+38.57%+9.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$15.70181.66% UpsideCNTACentessa Pharmaceuticals 2.21Hold$41.334.24% UpsideSRRKScholar Rock 3.12Buy$56.0025.99% UpsideTGTXTG Therapeutics 2.71Moderate Buy$52.5030.27% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, CNTA, SRRK, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026TGTXTG Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/27/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.005/8/2026SRRKScholar Rock BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $55.005/8/2026SRRKScholar Rock HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $65.005/6/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $70.005/1/2026TGTXTG Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/1/2026TGTXTG Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026SRRKScholar Rock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026SRRKScholar Rock Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$62.004/20/2026ARDXArdelyx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTACentessa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$427.68M3.22N/AN/A$0.69 per share8.08CNTACentessa Pharmaceuticals$15M394.49N/AN/A$3.92 per share10.12SRRKScholar RockN/AN/AN/AN/A$2.41 per shareN/ATGTXTG Therapeutics$700.35M8.81$2.82 per share14.31$4.08 per share9.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$61.60M-$0.23N/A10.52N/A-13.58%-38.11%-11.85%8/3/2026 (Estimated)CNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)SRRKScholar Rock-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%8/5/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8614.0614.50N/A65.95%88.73%43.44%8/3/2026 (Estimated)Latest ARDX, CNTA, SRRK, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026SRRKScholar Rock-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 million3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.373.493.28CNTACentessa Pharmaceuticals0.239.539.53SRRKScholar Rock0.718.648.64TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%CNTACentessa Pharmaceuticals82.01%SRRKScholar Rock91.08%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.30%CNTACentessa Pharmaceuticals4.09%SRRKScholar Rock13.30%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90247.03 million233.94 millionOptionableCNTACentessa Pharmaceuticals200149.23 million143.13 millionOptionableSRRKScholar Rock140119.83 million103.89 millionOptionableTGTXTG Therapeutics290153.08 million136.80 millionOptionableARDX, CNTA, SRRK, and TGTX HeadlinesRecent News About These CompaniesWhy Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?June 5 at 12:35 PM | zacks.comTG Therapeutics rises on early-stage trial data for Briumvi injectableJune 4 at 8:06 PM | seekingalpha.comTGTX Stock Applies Brakes On 5-Session Losing Streak – Retail Eyes ‘Multi-Billion’ Sales As At-Home Multiple Sclerosis Treatment Gets BoostJune 4 at 3:05 PM | finance.yahoo.comTGTX Stock Up on Positive Phase I Data for Subcutaneous BriumviJune 4 at 12:01 PM | zacks.comTG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking EventJune 4 at 9:13 AM | seekingalpha.comTG Therapeutics Stock Surges After Drug Trial UpdateJune 3 at 3:50 PM | benzinga.comTG Therapeutics Stock Surges After Drug Trial UpdateJune 3 at 3:19 PM | benzinga.comTG Therapeutics Announces Positive Phase 1 Results for Subcutaneous BRIUMVI, Supporting Ongoing Phase 3 Trial Dosing RegimenJune 3 at 7:50 AM | quiverquant.comQTG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)June 3 at 7:30 AM | globenewswire.comTG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare ConferenceJune 2 at 7:30 AM | globenewswire.comTG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in ...June 1, 2026 | finance.yahoo.comTG Therapeutics Reports Significant Efficacy of BRIUMVI in Treating Treatment-Naïve Patients with Relapsing Multiple SclerosisJune 1, 2026 | quiverquant.comQTG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in ImmunologyJune 1, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Apogee Therapeutics (APGE) and Boston Scientific (BSX)May 30, 2026 | theglobeandmail.comTG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 OutlookMay 28, 2026 | seekingalpha.comTGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS StudyMay 28, 2026 | zacks.comTG Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comTG Therapeutics, Inc.: TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE TrialMay 27, 2026 | finanznachrichten.deTG Therapeutics Inc Stock GuidanceMay 27, 2026 | benzinga.comTG Therapeutics posts late-stage trial win for Briumvi single infusion regimenMay 27, 2026 | seekingalpha.comQ2 EPS Estimates for TG Therapeutics Increased by AnalystMay 8, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, CNTA, SRRK, and TGTX Company DescriptionsArdelyx NASDAQ:ARDX$5.56 +0.16 (+2.96%) Closing price 04:00 PM EasternExtended Trading$5.57 +0.01 (+0.18%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Centessa Pharmaceuticals NASDAQ:CNTA$39.62 -0.18 (-0.45%) Closing price 04:00 PM EasternExtended Trading$39.62 0.00 (0.00%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Scholar Rock NASDAQ:SRRK$44.30 -1.03 (-2.27%) Closing price 04:00 PM EasternExtended Trading$44.30 0.00 (0.00%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.TG Therapeutics NASDAQ:TGTX$40.16 -0.40 (-0.99%) Closing price 04:00 PM EasternExtended Trading$40.08 -0.08 (-0.20%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
